LON:TILS

Tiziana Life Sciences (TILS) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
58.50
58.50
52-Week Range
N/A
Volume
297,127 shs
Average Volume
522,223 shs
Market Capitalization
£113.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TILS stock logo

About Tiziana Life Sciences Stock (LON:TILS)

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

TILS Stock News Headlines

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Tiziana Life Sciences Ltd (0RP)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Tiziana Life Sciences CEO purchases shares
Tiziana Life Sciences
Advan Co Ltd (7463)
Tiziana Life Sciences: Multiple Sclerosis single study
See More Headlines
Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/30/2020
Today
4/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-3,595,000.00
Book Value
GBX 23.50 per share

Miscellaneous

Free Float
N/A
Market Cap
£113.85 million
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gabriele Marco Antonio Cerrone M.B.A. (Age 49)
    MBA, Founder & Exec. Chairman
    Comp: $13.76M
  • Dr. Kunwar Shailubhai (Age 63)
    CEO, Chief Scientific Officer & Exec. Director
    Comp: $810k
  • Dr. Andrea Brancale
    Scientific Founder
  • Mr. Richard Clarkson Ph.D.
    Scientific Founder
  • Mr. Andrew Westwell Ph.D.
    Scientific Founder
  • Ms. Keeren Shah (Age 44)
    Fin. Director
  • Dr. Thomas H. Adams (Age 78)
    Head of Drug Devel. & Exec. Director
  • Dr. Neil Graham M.P.H. (Age 62)
    MBBS, M.D., MPH, Chief Medical Officer
  • Dr. Napoleone Ferrara (Age 63)
    Chairman of Scientific Advisory Board
  • Prof. Roberto Pellicciari
    Consultant

TILS Stock Analysis - Frequently Asked Questions

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) posted its earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) EPS for the quarter, topping the consensus estimate of ($4.00) by $1.40.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV).

How do I buy shares of Tiziana Life Sciences?

Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:TILS) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners